Mechanisms of acquired resistance to 2-(4-Amino-3-methylphenyl) benzothiazole in breast cancer cell lines

Breast Cancer Research and Treatment

Volumn 110, Issue 1, 2008, Pages 57-68

  Bradshaw, Tracey D ^a   Stone, Erica L ^a   Trapani, Valentina ^a   Leong, Chee Onn ^a   Matthews, Charles S ^a   Te Poele, Robert ^b   Stevens, Malcolm F G ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Acquired resistance; Aryl hydrocarbon receptor; Benzothiazole; Breast cancer; Phortress

Indexed keywords

2 (4 AMINO 3 CYANOPHENYLPHENYL)BENZOTHIAZOLE; 2 (4 AMINO 3 IODOPHENYL)BENZOTHIAZOLE; 2 (4 AMINO 3 METHYLPHENYL) 5 FLUOROBENZOTHIAZOLE; 2 (4 AMINO 3 METHYLPHENYL)BENZOTHIAZOLE; ANTINEOPLASTIC AGENT; AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; DOXORUBICIN;

ARTICLE; BREAST CANCER; CANCER CELL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOCHROME P450 1A1 GENE; CYTOCHROME P450 1B1 GENE; DNA ADDUCT; DNA STRAND BREAKAGE; DRUG SENSITIVITY; GENE; GENETIC TRANSCRIPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION; WILD TYPE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; BENZOTHIAZOLES; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DNA ADDUCTS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; RECEPTORS, ARYL HYDROCARBON; TETRACHLORODIBENZODIOXIN;

EID: 44849142072     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9690-9     Document Type: Article

References (34)

1. Goldie JH, Coldman AJ (1998) Molecular aspects of drug resistance. In Drug Resistance in Cancer. Mechanisms and Models, Cambridge University Press, UK, pp 59-89
2. Mashima T, Tsuruo T (2005) Defects of the apoptotic pathway as therapeutic target against cancer. Drug Resist Updat 8:339-343
3. Cowan KH, Goldsmith ME, Levine RM, Aitken SC, Douglass E, Clendeninn N, Niehuis AW, Lippman NE (1982) Dihydrofolate reductase gene amplification and possible rearrangement in estrogen-responsive methotrexate-resistant human breast cancer cells. J Biol Chem 257:15079-15086
4. Akman SA, Forrest G, Chu FF, Esworthy S, Doroshow JH (1990) Antioxidant and xenobiotic-metabolizing enzyme gene expression in doxorubicin-resistant MCF-7 breast cancer cells. Cancer Res 50:1397-1402
5. Katzenellebogen BS, Kendra KL, Norman MJ, Berthois Y (1987) Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res 47:4355-4360
6. Jiang S, Wolf DM, Yingling JM, Chang C, Jordan VC (1992) An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol 90:77-86
7. Cowan KH, Batist G, Talpule A, Sinha BK, Myers CE (1986) Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 83:9328-9332
8. Moore M, Wang X, Lu Y-F, Wormke M, Craig A, Gerlach JH, Burghardt R, Barhoumi R, Safe S (1994) Benzo[a]pyrene-resistant MCF-7 human breast cancer cells. J Biol Chem 269:11751-11759
9. Trapani V, Patel V, Leong CO, Ciolino HP, Yeh GC, Hose C, Trepel JB, Stevens MFG, Sausville EA, Loaiza-Perez AI (2003) DNA damage and cell cycle arrest induced by 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is attenuated in aryl hydrocarbon receptor deficient MCF-7 cells. Br J Cancer 88:599-605
10. Bradshaw TD, Westwell AD (2004) The development of the antitumour benzothiazole prodrug, Phortress, as a clinical candidate. Curr Med Chem 11:1009-1023
11. Bradshaw TD, Fichtner I, Bibby MJ, Double JA, Cooper PA, Alley MC, Tomaszewjski JE, Donahue S, Stinson SF, Sausville EA, Stevens MFG (2002) Preclinical evaluation of amino acid prodrugs of novel antitumor 2-(4-amino-3-methylphenyl)benzothiazoles. Mol Cancer Ther 1:239-246
12. Bradshaw TD, Chua M-S, Browne HL, Trapani V, Sausville EA, Stevens MFG (2002) In vitro evaluation of amino acid prodrugs of novel antitumour 2-(4-amino-3-methylphenyl)benzothiazoles. Br J Cancer 86:1348-1354
13. Loaiza-Perez A, Trapani V, Hose C, Singh SS, Trepel J, Stevens MFG, Bradshaw TD, Sausville EA (2002) The aryl hydrocarbon receptor mediates sensitivity of MCF-7 breast cancer cells to the antitumor agent 2-(4-aminophenyl)benzothiazole. Mol Pharmacol 61:13-19
14. Kashiyama E, Hutchinson I, Chua M-S, Stinson SF, Phillips LR, Kaur G, Sausville EA, Bradshaw TD, Westwell AD, Stevens MFG (1999) Antitumor benzothiazoles. 8. Synthesis, metabolic formation and biological properties of the C-and N-oxidation products of antitumor 2-(4-aminopheny)benzothiazoles. J Med Chem 42:4172-4184
15. Chua M-S, Kashiyama E, Bradshaw TD, Stinson SF, Brantley E, Sausville EA, Stevens MFG (2000) Role of CYP1A1 in modulation of antitumor properties of the novel agent 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) in human breast cancer cells. Cancer Res 60:5196-5203
16. Leong C-O, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC, Cooper PA, Double JA, Bradshaw TD, Stevens MFG (2003) Antitumour 2-(4-aminophenyl) benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo. Br J Cancer 88:470-477
17. Hutchinson I, Chua M-S, Browne HL, Trapani V, Bradshaw TD, Westwell AD, Stevens MFG (2001) Antitumor benzothiazoles. 14. The synthesis and in vitro biological properties of fluorinated 2-(4-aminophenyl)benzothiazoles. J Med Chem 44:1446-1455
18. Bradshaw TD, Wrigley S, Shi D-F, Schultz RJ, Paull KD, Stevens MFG (1998) 2-(4-Aminophenyl)benzothiazoles: novel agents with selective profiles of in vitro and in vivo activity. Br J Cancer 77:745-752
19. Fichtner I, Monks A, Hose C, Stevens MFG, Bradshaw TD (2004) The experimental antitumor agent Phortress and doxorubicin are equiactive against human-derived breast carcinoma xenograft models. Breast Cancer Res Treat 87:97-107
20. Berghard A, Gradin K, Pongratz I, Whitelaw M, Poellinger L (1993) Cross coupling of signal transduction pathways: the dioxin receptor mediates induction of cytochrome P-4501A1 expression via protein kinase C-dependent mechanism. Mol Cell Biol 13:677-689
21. Nordeen SK (1988) Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques 6:454-457
22. 32P-postlabeling analysis of aromatic carcinogen-DNA adducts. Cancer Res 45:5656-5662
23. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7:1543-1551
24. Clarke PA, te Poele R, Wooster R, Workman P (2001) Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem Pharmacol 62:1311-1336
25. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1988) DNA double-stranded breaks induce histone H2AX phosporylation on serine 139. J Biol Chem 273:5858-5868
26. Hayes JD, Wolf CR (1990) Molecular mechanisms of drug resistance. Biochem J 272:281-295
27. Yeh GC, Daschner PJ, Lopaczynska J, MacDonald CJ, Ciolino HP (2001) Modulation of glucose-6-phosphate dehydrogenase activity and expression is associated with aryl hydrocarbon resistance in vitro. J Biol Chem 276:34708-34713
28. Degen GH, Vogel C, Abel J (2001) Prostaglandin synthases. In: Ioannides C (ed) Enzyme systems that metabolise drugs and other xenobiotics. John Wiley & Sons Ltd, pp 189-229
29. Leong C-O, Suggitt M, Swaine DJ, Bibby MC, Stevens MFG, Bradshaw TD (2004) In vitro, in vivo and in silico analyses of the antitumor activity of 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazoles. Mol Can Ther 3:1565-1575
30. Lockett KL, Hall MC, Xu J, Zheng SL, Berwick M, Chuang SC, Clark PE, Cramer SD, Lohmen K, Hu J (2004) The ADPRT V62A genetic variant contributes to prostate cancer susceptibility and deficient enzyme function. Cancer Res 64:6344-6348
31. McFadyen MCE, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI (2001) Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol 62:207-212
32. Rochat B, Morsman JM, Murray GI, Fiff WD, McLeod HL (2001) Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation. J. Phamacol Exp Ther 296:537-541
33. Bandiera S, Weidlich S, Harth V, Broede P, Ko Y, Friedberg T (2005) Proteasomal degradation of human CYP1B1: effect of the Asn435Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 67:435-443
34. Sissung TM, Price DK, Sparreboom A, Figg WD (2006) Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone-mediated tumor metabolism and a novel target for therapeutic intervention. Mol Can Res 4:135-150